These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1692896)

  • 21. [Therapeutic options in advanced cancer of the prostate].
    Schmid HP; Bitton A
    Praxis (Bern 1994); 1997 Oct; 86(44):1734-9. PubMed ID: 9446174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy.
    Soloway MS
    Prog Clin Biol Res; 1990; 350():141-8. PubMed ID: 2201040
    [No Abstract]   [Full Text] [Related]  

  • 24. LH-RH-endocrine manipulation in cancer of the prostate.
    Falcone T; Falutz G; Tolis G
    Biomed Pharmacother; 1982; 36(8-9):344-8. PubMed ID: 6303470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Managing side effects of androgene deprivation in prostate cancer].
    Thalgott M; Gschwend JE; Retz M
    MMW Fortschr Med; 2010 Oct; 152(41):40-3. PubMed ID: 21090376
    [No Abstract]   [Full Text] [Related]  

  • 27. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant androgen deprivation before radical prostatectomy. A review.
    Selli C; Milesi C
    Minerva Urol Nefrol; 2004 Jun; 56(2):165-71. PubMed ID: 15195024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Medical treatment of prostate cancer].
    Lobel B; Cipolla B; Labrador J
    Rev Prat; 1994 Mar; 44(5):611-5. PubMed ID: 8066398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
    Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
    BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should we follow-up serum testosterone in patients with advanced prostate cancer?
    Perachino M
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1031-5. PubMed ID: 20645692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
    Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
    Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigating the response of prostatic cancer to endocrine therapy.
    Shimazaki J; Isaka S; Akimoto S; Sumiya H; Masai M; Higa T
    Prog Clin Biol Res; 1990; 357():59-67. PubMed ID: 1699239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New development of endocrine therapy in prostate cancer].
    Naito S
    Gan To Kagaku Ryoho; 1996 May; 23(6):684-8. PubMed ID: 8645018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current topics and perspectives relating to hormone therapy for prostate cancer.
    Suzuki H; Kamiya N; Imamoto T; Kawamura K; Yano M; Takano M; Utsumi T; Naya Y; Ichikawa T
    Int J Clin Oncol; 2008 Oct; 13(5):401-10. PubMed ID: 18946750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in hormonal therapy for advanced prostate cancer.
    Oottamasathien S; Crawford ED
    Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Avoidance and management of positive surgical margins before, during and after radical prostatectomy.
    Bott SR; Kirby RS
    Prostate Cancer Prostatic Dis; 2002; 5(4):252-63. PubMed ID: 12627209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
    Messing EM; Manola J; Sarosdy M; Wilding G; Crawford ED; Trump D
    N Engl J Med; 1999 Dec; 341(24):1781-8. PubMed ID: 10588962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.